PMID- 17586413
OWN - NLM
STAT- MEDLINE
DCOM- 20071101
LR  - 20220408
IS  - 0895-7061 (Print)
IS  - 0895-7061 (Linking)
VI  - 20
IP  - 7
DP  - 2007 Jul
TI  - Effects of carvedilol versus metoprolol on endothelial function and oxidative 
      stress in patients with type 2 diabetes mellitus.
PG  - 777-83
AB  - BACKGROUND: Data suggest that carvedilol possesses antioxidant properties that 
      might provide vascular protection. We sought to compare the effects of carvedilol 
      and metoprolol tartrate on endothelial function and oxidative stress in a 
      head-to-head trial. METHODS: Thirty-four patients with type 2 diabetes mellitus 
      (T2DM) and hypertension were randomized to receive either carvedilol (n = 16) or 
      metoprolol (n = 18) in addition to their current antihypertensive medications for 
      5 months. The following variables were measured pre- and posttreatment: blood 
      pressure, fasting glucose and insulin, insulin resistance by homeostasis-model 
      assessment, hemoglobin A1c, lipids, C-reactive protein (CRP), 8-isoprostane, 
      asymmetric dimethylarginine, oxidized LDL cholesterol, ultrasound assessment of 
      brachial-artery flow-mediated dilation (FMD), nitroglycerin-induced 
      endothelium-independent dilation (EID), brachial and carotid artery distension, 
      distensibility and compliance, and carotid artery intima-media thickness (cIMT). 
      RESULTS: Both carvedilol and metoprolol treatment resulted in significant and 
      similar decreases in systolic (P < .05) and diastolic (P < .0001) blood pressure. 
      Compared with metoprolol, carvedilol significantly improved FMD (P < .001). No 
      differences between groups were noted for any of the glycemic or lipid variables 
      except for HDL cholesterol, which significantly decreased (P < .05) in the 
      metoprolol group compared with the carvedilol group. No differences were observed 
      between groups for CRP, the markers of oxidative stress, EID, arterial stiffness, 
      or cIMT. CONCLUSIONS: Compared with metoprolol, carvedilol significantly improves 
      endothelial function in patients with T2DM. Changes in glycemic control and 
      oxidative stress do not seem to explain the observed improvements in FMD, which 
      suggests that other mechanisms may be involved.
FAU - Bank, Alan J
AU  - Bank AJ
AD  - Department of Research, St. Paul Heart Clinic, St. Paul, Minnesota, USA. 
      abank@stphc.com
FAU - Kelly, Aaron S
AU  - Kelly AS
FAU - Thelen, Andrea M
AU  - Thelen AM
FAU - Kaiser, Daniel R
AU  - Kaiser DR
FAU - Gonzalez-Campoy, J Michael
AU  - Gonzalez-Campoy JM
LA  - eng
SI  - ClinicalTrials.gov/NCT00123604
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Hypertens
JT  - American journal of hypertension
JID - 8803676
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Carbazoles)
RN  - 0 (Propanolamines)
RN  - 0K47UL67F2 (Carvedilol)
RN  - GEB06NHM23 (Metoprolol)
SB  - IM
MH  - Aged
MH  - Antihypertensive Agents/*therapeutic use
MH  - Carbazoles/*therapeutic use
MH  - Carvedilol
MH  - Diabetes Mellitus, Type 2/complications/*physiopathology
MH  - Double-Blind Method
MH  - Endothelium, Vascular/*drug effects/physiology
MH  - Female
MH  - Humans
MH  - Hypertension/complications/*drug therapy
MH  - Male
MH  - Metoprolol/*therapeutic use
MH  - Middle Aged
MH  - Oxidative Stress/*drug effects
MH  - Propanolamines/*therapeutic use
EDAT- 2007/06/26 09:00
MHDA- 2007/11/02 09:00
CRDT- 2007/06/26 09:00
PHST- 2006/12/11 00:00 [received]
PHST- 2007/01/01 00:00 [revised]
PHST- 2007/01/25 00:00 [accepted]
PHST- 2007/06/26 09:00 [pubmed]
PHST- 2007/11/02 09:00 [medline]
PHST- 2007/06/26 09:00 [entrez]
AID - S0895-7061(07)00091-X [pii]
AID - 10.1016/j.amjhyper.2007.01.019 [doi]
PST - ppublish
SO  - Am J Hypertens. 2007 Jul;20(7):777-83. doi: 10.1016/j.amjhyper.2007.01.019.